NEW YORK (GenomeWeb News) – Protagen today said that it is working with German diagnostics firm Mikrogen on jointly developing infectious disease diagnostics based on Protagen's UNIarray platform.
The firms have conducted a feasibility study for identifying typical autoantibody signatures in infectious diseases that may be useful for diagnostic tests.
"The cooperation with Protagen secures Mikrogen the access to an important and novel technology platform," Erwin Soutschek, co-founder and managing director of Mikrogen, said in a statement. He added that the firms will joinly develop and market marker panels for differential diagnosis of relevant infectious diseases.
Dortmund, Germany-based Protagen has developed the UNIarray platform for developing serum-based diagnostics, as well as the UNIchip line of protein microarrays for development of antibodies.
Financial and other terms of the agreement were not disclosed.